Premium Information is available for this item - Upgrade for $1 a day
6505-01-131-5620
Multivitamin Solution For Injection
6505011315620 011315620 NDC00381-0243-05 42-05 NDC00469-0690-23
INC: 32581 Multivitamin Solution For Injection
January 2023
4
Marketplace 6505-01-131-5620
Request a Quotation from participating marketplace vendors
Related Documents 6505-01-131-5620 5+ Documents (More...)
RQST NE Updated Every Day 6505-01-131-5620 RQST Updated Every Day 6505-01-131-5620 RQST NE Related
Documents 6505-01-131-5620 5+ Documents ( More... ) https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505
-455-9955 RQST https 4941 6505-01-210-3639 https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-131-5620
Multivitamin Solution For Injection -6274 6505-01-131-5620 https//www.nsnlookup.com https//www.nsnlookup.com
Multivitamin Solution For Injection fsc-6505/us 6505-01-131-5620 -455-9955 RQST https 4941 6505
-01-210-3639 01-131-5620 For Injection,121-947 6505-12-331-6274 6505-01-131-5620 https//www.nsnlookup.com
Multivitamin Solution For Injection 6505-01-131-5620 -455-9955 RQST https 4941 6505 -01-210-3639
01-131-5620 For Injection,121-947 6505-12-331-6274 6505-01-131-5620 165-8917 6505-01-658-4941 6505-01
6274 Multivitamin Solution For Injection 6505-01-244-6589 Multivitamin Solution For Injection 6505-01-131-5620
165-8917 6505-01-658-4941 6505-01-210-3639 6505-01-244-6589 Injection,121-947 -6505/us 6505-01-131-5620
Restrictions 6505-01-131-5620
6505-01-131-5620 is a Multivitamin Solution For Injection that does not have a nuclear hardened feature or any other critical feature such as tolerance, fit restriction or application. Demilitarization of this item has been confirmed and is not currently subject to changes. This item is considered a low risk when released from the control of the Department of Defense. The item may still be subject to the requirements of the Export Administration Regulations (EAR) and the Code of Federal Regulations (CFR). This item may be hazardous as it is in a Federal Supply Class for potentially hazardous items. A MSDS should be available from the supplier for the end user to evaluate any hazards. The precious metals content of this item is unknown.
Import and Export 6505-01-131-5620
- Schedule B
- Subscribe to View Schedule B
- HTS Code
- Subscribe to View HTS Code
End Users 6505-01-131-5620
- MOE Rule:
- V542
- Effective Date:
- 1 Apr 1991
Approved Sources 6505-01-131-5620
- Part Number
- Manufacturer
- Status
- NDC00381-0243-05
- Manufacturer
- 25282 - Carter-Glogau Laboratories Inc (Active)
- Incomplete Reference
- Incomplete Reference
- 42-05
- 60567 - Lyphomed Inc Div Of Fujisawa Usa Inc (Obsolete)
- Primary Buy
- Primary Buy
- NDC00469-0690-23
- 60567 - Lyphomed Inc Div Of Fujisawa Usa Inc (Obsolete)
- Primary Buy
- Primary Buy
Datasheet 6505-01-131-5620
- Characteristic
- Specifications
- FIIG
- Specifications
- A45100
- Active Medicament Medicinal Strength [AKJA]
- 500.000 Milligrams Ascorbic Acid Active Ingredient And 25.000 Milligrams Dexpanthenol Active Ingredient And 100.000 Milligrams Niacinamide Active Ingredient And 15.000 Milligrams Pyridoxine Hydrochloride Active Ingredient And 10.000 Milligrams Riboflavin Active Ingredient And 50.000 Milligrams Thiamine Hydrochloride Active Ingredient And 10000.000 International Units Vitamin A Active Ingredient And 1000.000 International Units Vitamin D Active Ingredient And 5.000 International Units Vitamin E Active Ingredient
- Primary Container Type [CQCT]
- Vial
- Primary Container Content Quantity [CRLK]
- 5.000 Milliliters
- Special Features [FEAT]
- Concentrate To Be Diluted In Not Less Than 500 Ml Infusion Fluid
- Total Primary Container Quantity [CSCW]
- 25
Management Data 6505-01-131-5620
- Effective Date
- Organization
- Unit of Issue
- Unit Price
- Qty Unit Pack
- Unit of Issue
- Apr 1983
- Veterans Administration (VA)
- BX
- Subscribe
- BX
Similar Supply Items to 6505-01-131-5620
Freight Information 6505-01-131-5620
6505-01-131-5620 has freight characteristics.. 6505-01-131-5620 has a variance between NMFC and UFC when transported by rail and the description should be consulted.